ERBB2 and pulmonary arterial hypertension: A literature review revealed that several case reports and reviews have associated anti-HER2 therapies with PAH.40–42 Anti-HER2 therapies might induce hemorrhagic telangiectasia, disrupt cytoskeletal microtubules, and lead to apoptosis of potentially HER2‐expressing endothelial cells, potentially resulting in PAH.